Cirium Ascend Consultancy Lands ‘Appraiser of the Year’ Title for the 10th Time
14.1.2025 09:00:00 CET | Business Wire | Press release
2025 marks the third year in a row Cirium has been awarded the prestigious accolade, recognising their unparalleled expertise in the field
Cirium Ascend Consultancy, part of the world’s most trusted source of aviation analytics, Cirium, has once again landed Airline Economics’ prestigious title of ‘Appraiser of the Year’ at an award ceremony last night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113971776/en/
Cirium awarded 'Appraiser of the Year' (Photo: Business Wire)
This marks the tenth win for Cirium Ascend Consultancy, demonstrating its unparalleled expertise within aviation consultancy and underlining its unwavering commitment to excellence, transparency and accuracy.
The annual award was presented to Rob Morris, Global Head of Cirium Ascend Consultancy, at the Airline Economics Aviation 100 Global Leaders Awards 2025 in Dublin, Ireland, which celebrates the best companies, individuals and transactions in the aviation finance and leasing sector.
2025’s landmark win makes it the first time a single firm has won the title 10 times, recognising Cirium Ascend Consultancy’s invaluable insights that have shaped the strategies of key players in the industry.
Voters of this year’s award praised Cirium’s accurate, timely, and insightful aircraft appraisals that have provided the valuations and analysis needed to understand market outlook, evaluate risks, and identify opportunities.
Rob Morris, Global Head of Cirium Ascend Consultancy, said: “As we start 2025, we are humbled to have been named ‘Appraiser of the Year’ for the tenth time, reaching an impressive milestone in our history.
“Winning this prestigious accolade not only symbolises the trust and confidence our industry has in us, but is a tribute to the Ascend Consultancy team’s dedication and commitment throughout 2024. We have continued to strive for excellence, offering clients independent and transparent insights in a volatile year for OEMs, lessors, and the wider supply chain.”
Cirium Ascend Consultancy’s contributions extend beyond appraisals, encompassing various aspects of aviation analytics such as risk management, asset tracking, and sustainability evaluations. The firm’s innovative solutions, including CO2 emissions benchmarking and fuel consumption analysis, reflect its commitment to supporting the industry’s transition towards a more sustainable future.
With worldwide teams, and the industry’s largest team of ISTAT/ASA certified appraisers, Cirium Ascend Consultancy is poised to further drive industry analysis and improvement in 2025.
To find out more about Cirium Ascend Consultancy visit https://www.cirium.com/analytics-services/ascend-consultancy/
For Cirium media inquiries please contact media@cirium.com
About Cirium Ascend Consultancy
Cirium Ascend Consultancy, a division of Cirium, offers market-leading expertise to help inform and drive successful strategies in the commercial aviation industry. With a global team of seasoned consultants and analysts, Cirium Ascend Consultancy delivers comprehensive data, expert insights, and tailored services that directly impact strategic investments and open avenues for growth in aviation.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.
Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium® on LinkedIn or visit cirium.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113971776/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom